Logo image of PRLD

PRELUDE THERAPEUTICS INC (PRLD) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:PRLD - US74065P1012 - Common Stock

1.67 USD
+0.08 (+5.03%)
Last: 11/26/2025, 8:00:01 PM
1.67 USD
0 (0%)
After Hours: 11/26/2025, 8:00:01 PM
Fundamental Rating

2

Overall PRLD gets a fundamental rating of 2 out of 10. We evaluated PRLD against 533 industry peers in the Biotechnology industry. While PRLD seems to be doing ok healthwise, there are quite some concerns on its profitability. PRLD does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

PRLD had negative earnings in the past year.
PRLD had a negative operating cash flow in the past year.
In the past 5 years PRLD always reported negative net income.
PRLD had a negative operating cash flow in each of the past 5 years.
PRLD Yearly Net Income VS EBIT VS OCF VS FCFPRLD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

Looking at the Return On Assets, with a value of -134.21%, PRLD is doing worse than 82.93% of the companies in the same industry.
The Return On Equity of PRLD (-217.26%) is worse than 68.86% of its industry peers.
Industry RankSector Rank
ROA -134.21%
ROE -217.26%
ROIC N/A
ROA(3y)-56.23%
ROA(5y)-46.15%
ROE(3y)-69.07%
ROE(5y)-54.62%
ROIC(3y)N/A
ROIC(5y)N/A
PRLD Yearly ROA, ROE, ROICPRLD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

PRLD does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PRLD Yearly Profit, Operating, Gross MarginsPRLD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -500 -1K -1.5K

More info and screens

5

2. Health

2.1 Basic Checks

PRLD does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, PRLD has more shares outstanding
The number of shares outstanding for PRLD has been increased compared to 5 years ago.
PRLD has a worse debt/assets ratio than last year.
PRLD Yearly Shares OutstandingPRLD Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
PRLD Yearly Total Debt VS Total AssetsPRLD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

PRLD has an Altman-Z score of -12.39. This is a bad value and indicates that PRLD is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -12.39, PRLD is doing worse than 76.17% of the companies in the same industry.
PRLD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -12.39
ROIC/WACCN/A
WACC8.64%
PRLD Yearly LT Debt VS Equity VS FCFPRLD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

PRLD has a Current Ratio of 3.21. This indicates that PRLD is financially healthy and has no problem in meeting its short term obligations.
PRLD has a Current ratio of 3.21. This is in the lower half of the industry: PRLD underperforms 61.35% of its industry peers.
PRLD has a Quick Ratio of 3.21. This indicates that PRLD is financially healthy and has no problem in meeting its short term obligations.
PRLD has a Quick ratio of 3.21. This is comparable to the rest of the industry: PRLD outperforms 41.46% of its industry peers.
Industry RankSector Rank
Current Ratio 3.21
Quick Ratio 3.21
PRLD Yearly Current Assets VS Current LiabilitesPRLD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

3

3. Growth

3.1 Past

PRLD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 16.95%, which is quite good.
EPS 1Y (TTM)16.95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%39.53%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%116.67%

3.2 Future

PRLD is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 7.99% yearly.
The Revenue is expected to grow by 103.00% on average over the next years. This is a very strong growth
EPS Next Y16.66%
EPS Next 2Y19.33%
EPS Next 3Y14.63%
EPS Next 5Y7.99%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y103%

3.3 Evolution

PRLD Yearly Revenue VS EstimatesPRLD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2024 2028 2029 2030 2031 2032 50M 100M 150M 200M
PRLD Yearly EPS VS EstimatesPRLD Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -1 -2 -3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PRLD. In the last year negative earnings were reported.
Also next year PRLD is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PRLD Price Earnings VS Forward Price EarningsPRLD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PRLD Per share dataPRLD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1 -1.5

4.3 Compensation for Growth

A more expensive valuation may be justified as PRLD's earnings are expected to grow with 14.63% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.33%
EPS Next 3Y14.63%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PRLD!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PRELUDE THERAPEUTICS INC

NASDAQ:PRLD (11/26/2025, 8:00:01 PM)

After market: 1.67 0 (0%)

1.67

+0.08 (+5.03%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2025-11-12/bmo
Earnings (Next)03-09 2026-03-09/amc
Inst Owners37.4%
Inst Owner Change-2.62%
Ins Owners11.34%
Ins Owner Change0.36%
Market Cap104.99M
Revenue(TTM)7.00M
Net Income(TTM)-127.17M
Analysts80
Price Target4.08 (144.31%)
Short Float %2.03%
Short Ratio0.35
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)19.38%
Min EPS beat(2)8.54%
Max EPS beat(2)30.21%
EPS beat(4)4
Avg EPS beat(4)17.61%
Min EPS beat(4)8.54%
Max EPS beat(4)30.21%
EPS beat(8)7
Avg EPS beat(8)12.41%
EPS beat(12)11
Avg EPS beat(12)13.6%
EPS beat(16)14
Avg EPS beat(16)10.99%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)14.29%
PT rev (3m)14.29%
EPS NQ rev (1m)88.65%
EPS NQ rev (3m)90.88%
EPS NY rev (1m)0%
EPS NY rev (3m)11.26%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 15
P/FCF N/A
P/OCF N/A
P/B 1.79
P/tB 1.79
EV/EBITDA N/A
EPS(TTM)-1.47
EYN/A
EPS(NY)-0.97
Fwd EYN/A
FCF(TTM)-1.6
FCFYN/A
OCF(TTM)-1.59
OCFYN/A
SpS0.11
BVpS0.93
TBVpS0.93
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -134.21%
ROE -217.26%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-56.23%
ROA(5y)-46.15%
ROE(3y)-69.07%
ROE(5y)-54.62%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.07
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 6.73%
Cap/Sales 1.71%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.21
Quick Ratio 3.21
Altman-Z -12.39
F-Score4
WACC8.64%
ROIC/WACCN/A
Cap/Depr(3y)190.81%
Cap/Depr(5y)187.88%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)16.95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%39.53%
EPS Next Y16.66%
EPS Next 2Y19.33%
EPS Next 3Y14.63%
EPS Next 5Y7.99%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%116.67%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y103%
EBIT growth 1Y-5.62%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-15.26%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y8.16%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y5.88%
OCF growth 3YN/A
OCF growth 5YN/A

PRELUDE THERAPEUTICS INC / PRLD FAQ

What is the fundamental rating for PRLD stock?

ChartMill assigns a fundamental rating of 2 / 10 to PRLD.


What is the valuation status of PRELUDE THERAPEUTICS INC (PRLD) stock?

ChartMill assigns a valuation rating of 0 / 10 to PRELUDE THERAPEUTICS INC (PRLD). This can be considered as Overvalued.


What is the profitability of PRLD stock?

PRELUDE THERAPEUTICS INC (PRLD) has a profitability rating of 0 / 10.


What is the expected EPS growth for PRELUDE THERAPEUTICS INC (PRLD) stock?

The Earnings per Share (EPS) of PRELUDE THERAPEUTICS INC (PRLD) is expected to grow by 16.66% in the next year.